Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 23071545 | HLA (HLA) | parkinson disease | NA | NA | NA | unclassified | |
| the recent parkinson disease gwas consortium meta-analysis and replication study reports association at several previously confirmed risk loci snca, mapt, gak/dgkq, and hla and identified a novel risk locus at rit2. | |||||||
| 23771222 | HLA-DR (HLA-DR) | parkinson disease | NA | NA | NA | unclassified | |
| human leukocyte antigen-dr induction and lymphocyte infiltrates in the brains of patients with parkinson disease (pd) and the presence in serum of a-synuclein (a-syn)-specific antibodies suggest that the peripheral immune system may have an active role in the progression of pd. | |||||||
| 24183452 | HLA (HLA) | rs2395163 | NA | rs3129882 | rs9268515 | unclassified | |
| NA | |||||||
| 28981958 | HLA-DRB1 (HLA-DRB1) | parkinson disease | NA | NA | rs660895 | unclassified | |
| pooled analysis of the hla-drb1 by smoking interaction in parkinson disease. | |||||||
| 29162163 | HLA-DR (HLA-DR) | parkinson disease | NA | NA | NA | unclassified | |
| genetic variation in a major histocompatibility complex ii (mhcii)-encoding gene (hla-dr) increases risk for parkinson disease (pd), and the accumulation of mhcii-expressing immune cells in the brain correlates with a-synuclein inclusions. | |||||||
| 15613151 | HLA (HLA) | prader-willi syndrome | NA | NA | NA | unclassified | |
| four patients with clinically and genetically confirmed prader-willi syndrome (pws) underwent nocturnal polysomnograpy (psg), multiple sleep latency test (mslt), human leukocyte antigens (hla) typing and estimation of cerebrospinal fluid (csf) hypocretin-1 (hcrt-1) level to investigate if a role of hypothalamic dysfunction and sleep disturbance might be functionally connected through the hypocretin (orexin) system. | |||||||
| 22144960 | HLA-DR (HLA-DR) | neurological disorders | NA | NA | NA | negation | |
| validation of these concepts did not occur until 1987 when hla-dr was identified on activated microglia in a spectrum of neurological disorders. | |||||||
| 27153397 | HLA (HLA) | neurological disorders | NA | NA | NA | unclassified | |
| targeted bis-seq confirmed hap-asm in 12/13 loci tested, including ccdc155, cd69, frmd1, irf1, kbtbd11, and s100a(*)-ilf2, associated with immune phenotypes, myt1l, ptprn2, cmtm8 and celf2, associated with neurological disorders, ngfr and hla-drb6, associated with both immunological and brain disorders, and zfp57, a trans-acting regulator of genomic imprinting. | |||||||
| 27153397 | HLA (HLA) | brain disorders | NA | NA | NA | unclassified | |
| targeted bis-seq confirmed hap-asm in 12/13 loci tested, including ccdc155, cd69, frmd1, irf1, kbtbd11, and s100a(*)-ilf2, associated with immune phenotypes, myt1l, ptprn2, cmtm8 and celf2, associated with neurological disorders, ngfr and hla-drb6, associated with both immunological and brain disorders, and zfp57, a trans-acting regulator of genomic imprinting. | |||||||
| 30380510 | HLA-DR (HLA-DR) | neurological disorders | NA | NA | NA | positive+negation | |
| hla-dr (human leukocyte antigen-antigen d related) has been shown to play a significant role in several inflammatory and neurological disorders; however, the role of hla-dr signaling in asd has not yet been fully clarified. | |||||||
Copyright 2024